Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
ESMO Open|September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trialAndrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
British Journal of Cancer|June 28, 2017
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancerDaniele Oddo, Giulia Siravegna, Annunziata Gloghini, et al.
Nature|June 23, 2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerSandra Misale, Rona Yaeger, Sebastijan Hobor, et al.
Cancer Discovery|December 9, 2015
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal CancerMariangela Russo, Giulia Siravegna, Lawrence S Blaszkowsky, et al.
Cancer Discovery|May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer PatientsGiovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Clinical Colorectal Cancer|September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal CancerFederica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Targeted Oncology|July 3, 2017
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution ExperienceAndrea Sartore-Bianchi, Alessio Amatu, Erica Bonazzina, et al.
The Lancet. Oncology|April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, et al.
Pageof 5